PURPOSE: To examine the association between serum C-peptide, a marker of insulin secretion, measured 3 years after a breast cancer diagnosis, and death resulting from all causes and breast cancer. PATIENTS AND METHODS: This was a prospective, observational study of 604 women enrolled onto the Health, Eating, Activity, and Lifestyle (HEAL) Study who were diagnosed with local or regional breast cancer between 1995 and 1998 and observed until death or December 31, 2006, whichever came first. The hazard ratio (HR) for all deaths and deaths owing to breast cancer and 95% CIs for the HR were estimated using multivariable stratified Cox regression analyses. RESULTS: Among women without type 2 diabetes, fasting C-peptide levels were associated with an increased risk of death resulting from all causes and from breast cancer. A 1-ng/mL increase in C-peptide was associated with a 31% increased risk of any death (HR = 1.31; 95% CI, 1.06 to 1.63; P = .013) and a 35% increased risk of death as a result of breast cancer (HR = 1.35; 95% CI, 1.02 to 1.87, P = .048). Associations between C-peptide levels and death as a result of breast cancer were stronger in certain subgroups, including women with type 2 diabetes, women with a body mass index less than 25 kg/m(2), women diagnosed with a higher stage of disease, and women whose tumors were estrogen receptor positive. CONCLUSION: Treatment strategies to reduce C-peptide levels in patients with breast cancer, including dietary-induced weight loss, physical activity, and/or use of insulin-lowering medications, should be explored.
PURPOSE: To examine the association between serum C-peptide, a marker of insulin secretion, measured 3 years after a breast cancer diagnosis, and death resulting from all causes and breast cancer. PATIENTS AND METHODS: This was a prospective, observational study of 604 women enrolled onto the Health, Eating, Activity, and Lifestyle (HEAL) Study who were diagnosed with local or regional breast cancer between 1995 and 1998 and observed until death or December 31, 2006, whichever came first. The hazard ratio (HR) for all deaths and deaths owing to breast cancer and 95% CIs for the HR were estimated using multivariable stratified Cox regression analyses. RESULTS: Among women without type 2 diabetes, fasting C-peptide levels were associated with an increased risk of death resulting from all causes and from breast cancer. A 1-ng/mL increase in C-peptide was associated with a 31% increased risk of any death (HR = 1.31; 95% CI, 1.06 to 1.63; P = .013) and a 35% increased risk of death as a result of breast cancer (HR = 1.35; 95% CI, 1.02 to 1.87, P = .048). Associations between C-peptide levels and death as a result of breast cancer were stronger in certain subgroups, including women with type 2 diabetes, women with a body mass index less than 25 kg/m(2), women diagnosed with a higher stage of disease, and women whose tumors were estrogen receptor positive. CONCLUSION: Treatment strategies to reduce C-peptide levels in patients with breast cancer, including dietary-induced weight loss, physical activity, and/or use of insulin-lowering medications, should be explored.
Authors: Melinda L Irwin; Anne McTiernan; Leslie Bernstein; Frank D Gilliland; Richard Baumgartner; Kathy Baumgartner; Rachel Ballard-Barbash Journal: Med Sci Sports Exerc Date: 2004-09 Impact factor: 5.411
Authors: Anne McTiernan; Kumar B Rajan; Shelley S Tworoger; Melinda Irwin; Leslie Bernstein; Richard Baumgartner; Frank Gilliland; Frank Z Stanczyk; Yutaka Yasui; Rachel Ballard-Barbash Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Karin B Michels; Caren G Solomon; Frank B Hu; Bernard A Rosner; Susan E Hankinson; Graham A Colditz; JoAnn E Manson Journal: Diabetes Care Date: 2003-06 Impact factor: 19.112
Authors: Melinda L Irwin; Diane Crumley; Anne McTiernan; Leslie Bernstein; Richard Baumgartner; Frank D Gilliland; Andrea Kriska; Rachel Ballard-Barbash Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Gadi Shlomai; Zara Zelenko; Irini Markella Antoniou; Marilyn Stasinopoulos; Aviva Tobin-Hess; Michael P Vitek; Derek LeRoith; Emily Jane Gallagher Journal: Endocr Relat Cancer Date: 2017-10 Impact factor: 5.678
Authors: Haiyun Wang; Shijia Zhang; Douglas Yee; Saonli Basu; Heather Beckwith; David Potter; Anne Blaes Journal: Breast Cancer Date: 2021-01-02 Impact factor: 4.239
Authors: Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872
Authors: Víctor Manuel Vargas-Hernández; Vm Vargas-Aguilar; Mario Adanm Moreno-Eutimio; Gustavo Acosta-Altamirano; Jm Tovar-Rodriguez Journal: Gland Surg Date: 2013-05
Authors: Stephanie M George; Leslie Bernstein; Ashley W Smith; Marian L Neuhouser; Kathy B Baumgartner; Richard N Baumgartner; Rachel Ballard-Barbash Journal: Breast Cancer Res Treat Date: 2014-07-24 Impact factor: 4.872